Nuron Biologics

Nuron Biologics was a biopharmaceutical company focused on the development and commercialization of biologics and vaccines for infectious and neurodegenerative diseases. Headquartered in Exton, Pennsylvania, the company aimed to address unmet medical needs by revitalizing established biologics and advancing novel vaccine candidates. Its portfolio included NU100, a recombinant interferon beta-1b for multiple sclerosis, and several vaccine programs acquired from Pfizer targeting meningococcal disease, Hib, and rabies. The company also explored early-stage research into a prophylactic vaccine for Alzheimer's disease. Although it secured significant royalty-based financing in its early years, Nuron Biologics is no longer active, with its founding leadership transitioning to other biotechnology ventures.